Publications:

Quantitative characterization of the mechanism of action and impact of a 'proteolysis-permitting' anti-PCSK9 antibody.

Mabs

Hansen, Ryan J RJ; Berna, Michael J MJ; Sperry, Andrea E AE; Beyer, Thomas P TP; Wroblewski, Victor J VJ; Schroeder, Krista M KM; Eacho, Patrick I PI

Publication Date: 2017

Variant appearance in text: PCSK9: R215A

PubMed Link: 27981884

Variant Present in the following documents:

• Main text
• kmab-09-02-1270490.pdf

View BVdb publication page

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.

Journal Of Lipid Research

Schroeder, Krista M KM; Beyer, Thomas P TP; Hansen, Ryan J RJ; Han, Bomie B; Pickard, Richard T RT; Wroblewski, Victor J VJ; Kowala, Mark C MC; Eacho, Patrick I PI

Publication Date: 2015-11

Variant appearance in text: PCSK9: R215A

PubMed Link: 26392590

Variant Present in the following documents:

• Main text

View BVdb publication page

Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.

The Journal Of Biological Chemistry

Lipari, Michael T MT; Li, Wei W; Moran, Paul P; Kong-Beltran, Monica M; Sai, Tao T; Lai, Joyce J; Lin, S Jack SJ; Kolumam, Ganesh G; Zavala-Solorio, Jose J; Izrael-Tomasevic, Anita A; Arnott, David D; Wang, Jianyong J; Peterson, Andrew S AS; Kirchhofer, Daniel D

Publication Date: 2012-12-21

Variant appearance in text: PCSK9: R215A

PubMed Link: 23135270

Variant Present in the following documents:

• Main text
• zbc43482.pdf

View BVdb publication page